🇺🇸 FDA
Patent

US 11655307

Anti-doublecortin-like kinase 1 antibodies and methods of use

granted A61KA61K2039/505A61K47/6871

Quick answer

US patent 11655307 (Anti-doublecortin-like kinase 1 antibodies and methods of use) held by The Board of Regents of the University of Oklahoma expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Oklahoma
Grant date
Tue May 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K2039/505, A61K47/6871, A61P, A61P35/00